CRM197 Protein Expression Method

A specific signal sequence for CRM197 protein expression in E. coli enables efficient secretion into the periplasm, overcoming production inefficiencies and toxicity issues, achieving high-yield, pure CRM197 protein with maintained properties.

JP7594057B2Active Publication Date: 2024-12-03GENOFOCUS CO LTD +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2023120482
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-09-03
Filing Date
2023-07-25
Publication Date
2024-12-03
Estimated Expiration
2039-10-02

AI Technical Summary

Technical Problem

Existing methods for producing CRM197 protein in E. coli result in degraded protein and are not efficient or cost-effective, and there is a need for a signal sequence that can efficiently express and secrete CRM197 into the periplasm while minimizing toxicity to the host cells.

Method used

A specific signal sequence, represented by amino acid sequences SEQ ID NO: 13 to SEQ ID NO: 21, is used to encode CRM197 protein, optimized for expression in E. coli, allowing efficient secretion into the periplasm without pH changes, using a nucleic acid structure or expression vector, and a recombinant microorganism to culture the CRM197 protein.

Benefits of technology

The method achieves high-yield, soluble expression and secretion of CRM197 protein into the periplasm, maintaining physicochemical and immunological properties similar to the native protein, with a purity of 99% and production efficiency up to 3.7 g/L without medium pH adjustments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594057000011
    Figure 0007594057000011
  • Figure 0007594057000012
    Figure 0007594057000012
  • Figure 0007594057000013
    Figure 0007594057000013
Patent Text Reader

Abstract

To provide a method for producing the CRM197 protein in an efficient and cost-effective manner.SOLUTION: The present invention provides: a signal sequence for expressing a CRM197 protein; a nucleic acid for encoding the signal sequence; a nucleic acid construct or expression vector comprising the nucleic acid and a CRM197 protein gene; a recombinant microorganism having the nucleic acid construct or expression vector introduced therein; and a CRM197 protein production method comprising a step for culturing the recombinant microorganism. According to the present invention, a CRM197 protein having the same physicochemical / immunologic properties as the protein isolated from the parent bacteria may be expressed even in regular Escherichia coli of which a redox potential is not adjusted, and a CRM197 protein having high periplasmic secretion efficiency may be produced even without shifting the pH of culture medium in order to increase secretion into the periplasm, and thus the present invention is very useful in CRM197 protein production.SELECTED DRAWING: Figure 4
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a signal sequence for expressing CRM197 protein in Escherichia coli and secreting it into the periplasm, and uses thereof. More specifically, the present invention relates to a signal sequence for expressing CRM197 protein, a nucleic acid encoding the signal sequence, a nucleic acid construct or expression vector containing the nucleic acid and a CRM197 protein gene, a recombinant microorganism into which the nucleic acid construct or expression vector has been introduced, and a method for producing CRM197 protein, which includes a step of culturing the recombinant microorganism. [Background technology]

[0002] Diphtheria toxin (DT) is a protein exotoxin synthesized and secreted by pathogenic strains of Corynebacterium diphtheriae. Diphtheria toxin is an ADP-ribosylating enzyme that is secreted as a proenzyme of 535 residues and separated into two fragments (A and B) by processing with a trypsin-like protease. Fragment A is an NAD-dependent ADP-ribosyltransferase that specifically targets the protein synthesis factor EF-2 at its catalytically active site, thereby inactivating EF-2 and disrupting protein synthesis in the cell.

[0003] CRM197 was discovered through the separation of multiple non-toxic and partially toxic immunologically cross-reactive forms (CRMs or cross-reacting substances) of diphtheria toxin (Uchida et al., Journal of Biological Chemistry 248, 3845-3850, 1973).Preferably, the CRMs can be of any size and composition, including the entire DT or a portion thereof.

[0004] CRM197 is a highly enzymatically inactive and non-toxic form of diphtheria toxin with a single amino acid substitution, G52E. This mutation imparts inherent flexibility to the active-site loop located in front of the NAD-binding site, thereby reducing CRM197's binding to NAD and abolishing DT toxicity (Malito et al., Proc Natl Acad Sci USA 109(14):5229-342012). CRM197, like DT, possesses two disulfide bonds. One disulfide bond connects Cys186 to Cys201, connecting fragment A to fragment B. The second disulfide bond connects Cys461 to Cys471 within fragment B. DT and CRM197 have nuclease activity due to fragment A (Bruce et al., Proc. Natl. Acad. Sci. USA 87, 2995-8, 1990).

[0005] Many antigens have low immunogenicity, especially in young children, unless chemically linked to a protein, and are therefore made into conjugates or conjugate vaccines. In such conjugate vaccines, the protein component is also called the "carrier protein." CRM197 is frequently used as a carrier protein in protein-carbohydrate conjugates and hapten-protein conjugates. As a carrier protein, CRM197 has many advantages over diphtheria toxoid as well as other toxoid proteins (Shinefield Vaccine, 28:4335, 2010).

[0006] Methods for the production of diphtheria toxin (DT) are well known in the art. For example, DT can be produced from cultures of Corynebacterium diphtheriae by purification of the toxin followed by chemical detoxification, or it can be produced by purification of a recombinant or genetically detoxified analog of the toxin.

[0007] The abundance of the protein has precluded the production of large quantities of diphtheria toxin such as CRM197 for use in vaccines. This problem has previously been addressed by expressing CRM197 in E. coli (Bishai, et al., J Bacteriol. 169:5140-5151), who described the expression of a recombinant fusion protein containing diphtheria toxin (including the tox signal sequence) that resulted in the production of a degraded protein.

[0008] Production of bacterial toxins in the periplasm, compared to cytoplasmic production, has the following advantages: i) the protein is produced in its mature form after cleavage of the signal peptide; ii) the periplasm of E. coli is an oxidative environment that allows for the formation of disulfide bonds, thus promoting the production of soluble, properly folded proteins; iii) the periplasm of E. coli contains fewer proteases than the cytoplasm, promoting the avoidance of proteolytic cleavage of the expressed protein; and iv) the periplasm contains fewer proteins, allowing for the production of purer recombinant proteins.

[0009] In general, the presence of a signal sequence on a protein promotes the transport of the protein to the periplasm (prokaryotic hosts) or secretion (eukaryotic hosts). In prokaryotic hosts, the signal sequence directs the nascent protein across the inner membrane to the periplasm, after which the signal sequence is cleaved. In other words, it is important to search for signal sequences that can more efficiently mass-produce commercially important proteins, and this is the reality that the development of recombinant microorganisms is required.

[0010] Therefore, the inventors have made extensive efforts to develop a method for producing CRM197 protein in an efficient and cost-effective manner, and as a result, they have selected a specific signal sequence and designed a base sequence by combining the codon context and secondary structure to optimize translation in E. coli, and the CRM197 base sequence encoding the CRM197 protein has also been optimized for expression in E. coli. They have confirmed that when these are used, CRM197 is efficiently expressed in E. coli and CRM197 is efficiently secreted into the periplasm even without pH changes, thereby completing the present invention.

[0011] The information provided in this Background section is intended to enhance understanding of the background of the invention only and, therefore, may not include information that constitutes prior art already known to those of ordinary skill in the art to which the invention pertains. Summary of the Invention [Problem to be solved by the invention]

[0012] The object of the present invention is to provide a signal sequence for expressing CRM197 protein of a specific sequence, a nucleic acid encoding the signal sequence, and a method for producing CRM197 protein using the nucleic acid, in order to secrete CRM197 protein into the periplasm of E. coli, minimize the toxicity of CRM197 protein to E. coli, and maximize expression. [Means for solving the problem]

[0013] To achieve the above object, the present invention provides a signal sequence for expressing CRM197 protein, which is represented by any one of the amino acid sequences of SEQ ID NO:13 to SEQ ID NO:21.

[0014] The present invention also provides a nucleic acid encoding a signal sequence for expressing the CRM197 protein.

[0015] The present invention also provides a nucleic acid construct or expression vector containing the nucleic acid and a CRM197 protein gene, a recombinant microorganism into which the nucleic acid construct or expression vector has been introduced, and a method for producing a CRM197 protein, the method comprising culturing the recombinant microorganism. [Brief description of the drawings]

[0016] [Figure 1] Schematic diagram of the expression module TPB1Tv1.3, where Ptrc stands for the trc promoter, RBS stands for A / U rich enhancer+SD, λtR2 & T7Te, rrnB T1T2 stands for transcription terminators, and BsaI and DraI stand for the restriction enzyme sites used during cloning.

[0017] [Diagram 2] 1 is a diagram showing the E. coli expression plasmid pHex1.3, in which Ori(pBR322) means the replication origin of pBR322, KanR means the kanamycin marker, lacI means the lacI gene, and the rest is the same as FIG. 1.

[0018] [Diagram 3] 1 is a schematic diagram of the construction of CRM197 expression plasmid, in which T1 represents λtR2 and T7Te transcription terminators, T2 represents rrnB T1T2 transcription terminators, the arrows represent PCR primers, and the letters A, B, C, and D represent homologous regions for LIC. The rest are the same as in FIG. 1.

[0019] [Figure 4]This figure shows the expression profile of L3, L5 fusion CRM197 in various E. coli strains, and shows Coomassie staining (left) and Western blotting (right) after SDS_PAGE of total cells of E. coli. C means C2894H, B means BL21(DE3), W means W3110-1, O means OrigamiTM2, and S means Shuffle. Cv means C2984H containing pHex1.3 used as a negative control, L3 and L5 mean fused signal sequences, and CRM197 means reference CRM197. For Coomassie staining, cells corresponding to 0.025 OD600 were loaded per well, and for Western blotting, cells corresponding to 0.0005 OD600 were loaded.

[0020] [Diagram 5] This figure shows the effect of inducer type and concentration on CRM197 expression induced by L5, and shows Coomassie staining (left) and Western blotting (right) after SDS-PAGE. The loading amount is the same as in Figure 4, I means insoluble fraction, and S means soluble fraction. (A) is cultured at 25°C, and (B) is cultured at 30°C.

[0021] [Figure 6] Figure 1 shows the location of CRM197 protein induced by L5 fusion. The upper panel shows Coomassie staining after SDS-PAGE, and the lower panel shows Western blotting. Cr indicates reference CRM197, and the arrow indicates the location of mature CRM197. P1 means the supernatant after treatment with plasma membrane induction buffer, P2 means the periplasmic fraction, and Cy means the cytoplasmic fraction.

[0022] [Figure 7] FIG. 1 shows the effect of inducer type and concentration on CRM197 expression induced by L3, (A) for 25° C. culture, and (B) for 30° C. culture.

[0023] [Figure 8] FIG. 1 shows the location of CRM197 protein induced by L3 fusion.

[0024] [Figure 9] This figure shows the changes in pH, temperature, impeller speed, and dissolved oxygen (DO) of the L3 strain, as well as the time of addition of the expression inducer. In (A), the temperature was maintained at 30°C, and in (B), the temperature was lowered to 25°C before expression induction.

[0025] [Figure 10] FIG. 1 shows the changes in pH, temperature, impeller speed, and dissolved oxygen (DO) of the L5 strain, as well as the time of addition of an expression inducer.

[0026] [Figure 11] This figure shows the change in CRM197 protein expression before and after the addition of an inducer during culture. (A) Expression of the L3 strain was induced at 30°C, (B) Expression of the L3 strain was induced at 25°C, and (C) Expression of the L5 strain was induced at 25°C. Line 3 and 10 in (A), line 4 and 10 in (B), and line 3 and 9 in (C) were loaded with 200 ng of reference CRM197. Line 1 and 2 in (A), line 1, 2, and 3 in (B), and line 1 and 2 in (C) are cell culture fluids before the addition of an inducer, line 16 in (A) and (C) are the supernatant after the end of culture, and the following lines are cell culture fluids sampled every 2 hours after the addition of the inducer. The loading amount is the same as in FIG. 4.

[0027] [Figure 12]Figure 1 shows the expression and separation behavior of CRM197 protein in L3 / L5 strains, (A) shows the separation behavior of protein in culture using L3, and (B) shows the separation behavior of protein in culture using L5. Line 1 shows the loading of 200 ng of reference CRM197, Line 2 shows the cell culture medium (total cells) after the end of culture, Line 3 shows the supernatant after treatment with plasma membrane induction buffer, Lines 4 and 7 show the periplasmic fraction (Line 7 was loaded with 4 times more protein than Line 4), and Lines 5 and 6 show the cytoplasmic fraction.

[0028] [Figure 13] The results of SDS-PAGE analysis of purified samples from DEAE chromatography (A) and HA chromatography (B). Line 1 in (A) is CRM197 produced in Corynebacteria, and line 2 is the protein present in the collected periplasmic fraction. Line 3 is the sample before loading for DEAE chromatography, which was concentrated 2-fold after ultrafiltration, and lines 4 and 5 are the impurity proteins excluding CRM197 in the flow-through mode and washing solution of DEAE chromatography. Line 6 is the eluted sample from which impurities were removed, and line 7 is the sample eluted using a high concentration of salt to remove all proteins bound to the resin. HA Elu in (B) is CRM197 eluted after removing proteins not bound to the HA resin.

[0029] [Figure 14] The final purified CRM197 was analyzed by SEC-HPLC and found to be 99% or higher in purity.

[0030] [Figure 15]SDS-PAGE (left) and Western blot (right) results. Line 1 is CRM197 produced in Corynebacterium, and Line 2 is CRM197 produced in E. coli (L3). Bands were confirmed at the same position for the two CRM197 strains.

[0031] [Figure 16] The molecular mass of the intact protein was analyzed by LC / MS, and the molecular weight was 58,409 Da, which was consistent with the theoretical molecular weight.

[0032] [Figure 17] Circular dichroism (CD) analysis confirmed that there was no difference in the higher-order structure between CRM197 (●) produced by Corynebacterium and CRM197 (Χ) produced by E. coli pHex-L3.

[0033] [Figure 18] The fluorescence spectrum analysis showed that CRM197 produced by Corynebacterium (●) and CRM197 produced by E. coli pHex-L3 (solid line) had the same maximum emission wavelength of 338 nm. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0034] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Generally, the nomenclature used herein is one that is well known and commonly used in the art.

[0035] In one embodiment of the present invention, expression was attempted by fusing nine signal sequences with the CRM197 protein. For each signal sequence, a base sequence (SEQ ID NO: 4 to SEQ ID NO: 12) optimized for translation was designed, taking into consideration the codon context and the secondary structure of mRNA. This construct was inserted into the expression plasmid pHex1.3, and the expression of CRM197 in five E. coli strains was investigated to find the optimal E. coli strain for each construct. In addition, the culture temperature, type and concentration of inducer were set for the selected E. coli. As a result, the above constructs were transformed into various E. coli strains, and the CRM197 protein was expressed in a soluble form even in strains in which genes related to redox potential (trxB, gor) were not manipulated, and it was possible to secrete it into the periplasm.

[0036] Therefore, in one aspect, the present invention relates to a signal sequence for expressing CRM197 protein, which is represented by any one of the amino acid sequences of SEQ ID NO:13 to SEQ ID NO:21.

[0037] In another aspect, the present invention relates to a nucleic acid encoding a signal sequence for expressing the CRM197 protein.

[0038] In the present invention, the nucleic acid may be characterized by being represented by any one of the base sequences of SEQ ID NO: 4 to SEQ ID NO: 12, and preferably by the base sequence of SEQ ID NO: 6 or SEQ ID NO: 8, but is not limited thereto.

[0039] As used herein, the term "signal sequence for CRM197 protein expression" refers to a signal sequence for the expression and secretion of CRM197 protein into the periplasm.

[0040] In one embodiment of the present invention, a signal sequence of a protein targeted to the outer membrane of E. coli and a signal sequence derived from M13 phage were selected to secrete CRM197 protein into the periplasm (Table 3). To optimize the translation of the selected signal sequences in E. coli, the base sequences were designed by combining the codon text and secondary structure (SEQ ID NO: 4 to SEQ ID NO: 12).

[0041] In still another aspect, the present invention relates to a nucleic acid construct comprising a nucleic acid encoding a signal sequence for expressing the CRM197 protein and a gene for the CRM197 protein.

[0042] In still another aspect, the present invention relates to an expression vector comprising a nucleic acid encoding a signal sequence for expressing the CRM197 protein and the CRM197 protein gene.

[0043] In one embodiment of the present invention, the DNA sequence encoding the amino acid sequence of CRM197 protein (SEQ ID NO: 3) was also optimized for expression in E. coli (SEQ ID NO: 2). DNA fragments of each designed signal sequence and the optimized CRM197 DNA fragment were inserted into plasmid pHex1.3 (Figure 3).

[0044] In the present invention, the gene for the CRM197 protein can be any gene that encodes the CRM197 protein without any limitations, and is preferably characterized by the base sequence of SEQ ID NO: 2, but is not limited thereto.

[0045] As used herein, "transformation" refers to the introduction of a specific foreign DNA strand from outside a cell into a cell. A host microorganism containing the introduced DNA strand is called a "transformed microorganism." "Transformation," which refers to the introduction of DNA into a host so that the DNA becomes replicable as an extrachromosomal factor or by chromosomal integration, refers to the introduction of a vector containing a polynucleotide encoding a target protein into a host cell, or the integration and completion of a polynucleotide encoding a target protein into a host cell chromosome so that the protein encoded by the polynucleotide can be expressed in the host cell. A transformed polynucleotide includes all of these, regardless of whether it is inserted and located within the host cell chromosome or located extrachromosomally, as long as it can be expressed in the host cell.

[0046] In the present invention, the "nucleic acid construct" includes all of these, regardless of whether it is inserted into the chromosome of the host cell or is located extrachromosomally, as long as it is capable of being expressed in the host cell.

[0047] In addition, in the present specification, the term "polynucleotide" is used interchangeably with "nucleic acid" and includes DNA and RNA encoding a target protein. The polynucleotide may be introduced into a host cell in any form as long as it can be introduced and expressed in the host cell. For example, the polynucleotide may be introduced into the host cell in the form of an expression cassette, which is a genetic structure containing all elements necessary for the polynucleotide to be expressed by itself. The expression cassette usually contains a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal operably linked to the polynucleotide. The expression cassette may be in the form of an expression vector capable of self-replicating. The polynucleotide may also be introduced into the host cell in its own form and operably linked to a sequence necessary for expression in the host cell.

[0048] As used herein, a "vector" refers to a DNA construct containing a DNA sequence operably linked to a suitable regulatory sequence capable of expressing the DNA in a suitable host. A vector may be a plasmid, a phage particle, or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or in some cases may integrate into the genome itself. In the present specification, the terms "plasmid" and "vector" are sometimes used interchangeably, since the plasmid is the most commonly used form of vector at present.

[0049] For the purposes of the present invention, it is preferable to use a plasmid vector. A typical plasmid vector that can be used for such purposes has a structure including (a) an origin of replication that allows efficient replication so that tens to hundreds of plasmid vectors are contained in one host cell, (b) an antibiotic resistance gene that allows host cells transformed with the plasmid vector to be selected, and (c) a restriction enzyme cleavage site that allows a foreign DNA fragment to be inserted. Even if a suitable restriction enzyme cleavage site does not exist, the vector and the foreign DNA can be easily ligated by using a synthetic oligonucleotide adaptor or linker by a conventional method.

[0050] Together, a gene is "operably linked" when it is placed in a functional relationship with another nucleic acid sequence. This can be a gene and regulatory sequences linked in a manner that allows expression of the gene when appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequences. For example, DNA for a pre-sequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a pre-protein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.

[0051] Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading frame; however, enhancers need not be contiguous. Linking of these sequences is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used by conventional techniques.

[0052] In the present invention, the expression vector may be characterized by further comprising a Trc promoter.

[0053] In the present invention, the expression vector may be characterized as pHex1.3, but is not limited thereto.

[0054] CRM197 has nuclease activity and is known to be highly toxic to E. coli. Therefore, expression of CRM197 under undesirable conditions may adversely affect the growth of E. coli. The E. coli expression plasmid pHex1.3 has a LacI gene and can suppress background expression of the trc promoter. The expression module TPB1Tv1.3 (FIG. 1) inserted into this plasmid has the tR2 transcription terminator derived from λ phage and the Te transcription terminator derived from T7 phage inserted upstream of the expressed CRM197 gene, and the rrnB T1T2 transcription terminator derived from E. coli inserted downstream, so that the expression of CRM197 transcribed from the promoter derived from the plasmid can be suppressed.

[0055] In yet another aspect, the present invention relates to a recombinant microorganism into which the nucleic acid construct or expression vector has been introduced.

[0056] In the present invention, the recombinant microorganism may be characterized as being Escherichia coli, but is not limited thereto.

[0057] As the recombinant microorganism, a host cell that has a high DNA introduction efficiency and a high expression efficiency of the introduced DNA is typically used. All microorganisms, including prokaryotic and eukaryotic cells, such as bacteria, yeast, and mold, can be used. Although Escherichia coli was used in the examples of the present invention, the present invention is not limited to this and any type of microorganism can be used as long as the CRM197 protein can be sufficiently expressed.

[0058] Of course, not all vectors function equally well to express the DNA sequences of the present invention, and similarly not all hosts function equally well with the same expression system. However, one skilled in the art can select from a variety of other vectors, expression control sequences, and hosts without undue experimental burden and without departing from the scope of the present invention. For example, in selecting a vector, the host must be considered, since the vector must replicate therein, and the number of copies of the vector, the ability to regulate the number of copies, and the expression of other proteins encoded by the vector, such as antibiotic markers, must also be considered.

[0059] The transformed recombinant microorganism can be produced by any commonly known transformation method.

[0060] In the present invention, the gene can be inserted into the chromosome of a host cell using a commonly known genetic engineering method, and examples thereof include a method using a retrovirus vector, an adenovirus vector, an adeno-associated virus vector, a herpes simplex virus vector, a fox virus vector, a lentivirus vector, or a non-viral vector.

[0061] In addition to the method using an expression vector, a method of directly inserting the nucleic acid construct into the chromosome of a host cell can also be used as a transformation method.

[0062] In general, electroporation, lipofection, ballistic delivery, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, chemically enhanced DNA entry, calcium phosphate (CaPO 4 ) precipitate, calcium chloride (CaCl 2 ) precipitation, microinjection, lithium acetate-DMSO method, etc. can be used.

[0063] Sonoporation, for example, using the Sonitron 2000 system (Rich-Mar), can also be used to deliver nucleic acids, and other representative nucleic acid delivery systems include those from Amaxa Biosystems (Cologne, Germany), Maxcyte, Inc. (Rockville, Maryland), and BTX Molecular System (Holliston, Mass.). Lipofection methods are disclosed in U.S. Pat. Nos. 5,049,386, 4,946,787, and 4,897,355. Lipofection reagents are also commercially available, for example, TRANSFECTAM™ and LIPOFECTIN™. Cationic or neutral lipids suitable for effective receptor-recognition lipofection of polynucleotides include Felgner's lipids (WO91 / 17424 and WO91 / 16024), which can be delivered to cells via in vitro delivery and to target tissues via in vivo delivery. Methods for producing lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, are well known in the art (Crystal, Science., 270:404-410, 1995; Blaese et al., Cancer Gene Ther., 2:291-297, 1995; Behr et al., Bioconjugate Chem., 5:382-389, 1994; Remy et al., Bioconjugate Chem., 5:647-654, 1994; Gao et al., Gene Therapy., 2:710-722, 1995; Ahmad et al., al., Cancer Res., 52:4817-4820, 1992; U.S. Patent No. 4,186,183; U.S. Patent No. 4,217,344; U.S. Patent No. 4,235,871; U.S. Patent No. 4,261,975; U.S. Patent No. 4,485,054; U.S. Patent No. 4,501,728; U.S. Patent No. 4,774,085; U.S. Patent No. 4,837,028; U.S. Patent No. 4,946,787).

[0064] In one embodiment of the present invention, the prepared plasmid vector was transformed into various E. coli strains (Table 4). As a result, in the case of L3 fusion, CRM197 was expressed in all strains, and in the case of L5 fusion, Origami TM CRM197 was expressed in all strains except strain 2 (Figure 4). All of the L3 and L5 fusions were able to express the CRM197 protein in soluble form, even in strains in which genes related to redox potential (trxB, gor) had not been manipulated, and the protein had the same physicochemical and immunological properties as the protein isolated from the parent strain. Furthermore, in the case of the L3 fusion, the CRM197 protein was expressed in soluble form not only at 25°C but also at 30°C (Figures 7 and 12A).

[0065] According to previous reports, secretion of CRM197 into the periplasm is improved when the pH is shifted to 7.5 during induction while culturing at 6.5-6.8. In contrast, efficient secretion of CRM197 into the periplasm was confirmed without changing the pH of the medium in the case of the strain produced in the present invention (FIG. 12). In the case of L5 fusion in high-concentration culture without pH shift, CRM197 productivity was 3.7 g / L, and CRM197 secreted into the periplasm was more than 2 g / L.

[0066] In yet another aspect, the present invention relates to a method for producing CRM197 protein, comprising: (a) culturing a recombinant microorganism into which the nucleic acid construct or expression vector has been introduced and producing CRM197 protein; and (b) recovering the produced CRM197 protein.

[0067] In the present invention, the step (b) may be characterized by recovering the CRM197 protein secreted into the periplasm.

[0068] The present invention will be described in more detail with reference to the following examples. It will be obvious to those skilled in the art that these examples are merely for the purpose of illustrating the present invention and are not intended to limit the scope of the present invention. EXAMPLES

[0069] Example 1: Construction of CRM197 overexpression plasmid

[0070] Example 1.1: Construction of plasmid pHex1.3

[0071] The E. coli expression plasmid pHex1.3 was constructed as follows. ptrc99a (Amann et al., Gene. 69, 301-15, 1988) was double digested with SspI and DraI, and the approximately 3.2 kb DNA fragment was purified using agarose electrophoresis. The kanamycin resistant gene was amplified by PCR. The template used was the plasmid pCR2.1, and the primers used were KF2 and KR (Table 1).

[0072] [Table 1] TIFF0007594057000002.tif154170

[0073] The PCR reaction conditions were 2.5 mM each dNTP, 10 pmol each primer, 200 ng to 500 ng template DNA, 1.25 U PrimeSTAR HS DNA polymerase (Takara Bio Inc., Japan), and 50 μl reaction volume. The PCR conditions were 98°C for 10 seconds, 60°C for 5 seconds, and 72°C min / kb, which were repeated 30 times. The approximately 0.8 kb DNA fragment generated under these PCR conditions was doubly cleaved with Bam Hi and HindIII, and then filled in with blunt ends using Klenow fragment, and ligated with the 3.2 kb DNA fragment generated in the previous step using T4 DNA ligase. This reaction solution was transformed into E. coli C2984H to produce pHex1.1, in which the selection marker was replaced from Amp to Km.

[0074] The expression module TPB1Bv1.3 (Figure 1), which includes a promoter, RBS, and transcription terminator, was synthesized by Bioneer (SEQ ID NO: 1). The process of incorporating the expression module TPB1Bv1.3 into pHex1.3 is as follows. A DNA fragment (1255 bp) obtained by PCR amplification using the expression module TPB1Bv1.3 as a template and TPB_F and TPB_R as primers (Table 1) and a DNA fragment (4561 bp) obtained by PCR amplification using pHex1.1 as a template and pHex_F and pHex_R as primers were assembled in vitro using ligation-independent cloning (LIC; Jeong et al., Appl Environ Microbiol. 78, 5440-3, 2012) under the conditions shown in Table 2, and then transformed into E. coli C2984H to produce pHex1.3 (Figure 2).

[0075] [Table 2]

[0076] LIC reaction conditions: The vector is cut with restriction enzymes or PCR is used to create linear DNA fragments. The insert is produced using PCR. The vector and insert are mixed as shown in the table above and reacted at room temperature for 2 minutes and 30 seconds.

[0077] Example 1.2: Production of the CRM197 gene

[0078] The nucleotide sequence of CRM197 (CRM197ec) optimized for expression in E. coli was synthesized using Genscript (SEQ ID NO: 2). The amino acid sequence encoded by CRM197ec is shown in SEQ ID NO: 3.

[0079] Example 1.3: Production of a signal sequence gene

[0080] The signal sequences used to secrete CRM197 protein into the periplasm of E. coli are shown in Table 3 below (SEQ ID NO: 13 to SEQ ID NO: 21). To optimize expression in E. coli, DNAs of SEQ ID NO: 4 to SEQ ID NO: 12 were synthesized taking into consideration the codon text and secondary structure (Table 3).

[0081] [Table 3] TIFF0007594057000005.tif66170

[0082] Example 1.4: Construction of plasmids for CRM197 overexpression

[0083] A plasmid for overexpressing CRM197 in E. coli and secreting it into the periplasm was constructed as shown in Figure 3. pHex1.3 was doubly digested with BsaI and DraI, and a DNA fragment of approximately 5 kb was isolated using agarose electrophoresis. Signal sequences L1 to L9 were amplified by PCR using the primers and templates in Table 1. CRM197 DNA fragments for fusing the CRM197 gene to each signal sequence using the LIC method were amplified by PCR using the primers and templates in Table 1. pHex1.3 digested with BsaI and DraI, each signal sequence fragment, and the CRM197 fragment compatible therewith were assembled in vitro using the LIC conditions described above, and then transformed into E. coli C2984H to produce plasmids pHex-L1-CRM, pHex-L2-CRM, pHex-L3-CRM, pHex-L4-CRM, pHex-L5-CRM, pHex-L6-CRM, pHex-L7-CRM, pHex-L8-CRM, and pHex-L9-CRM containing CRM197 fused to each signal sequence.

[0084] Example 2: Expression of CRM197 protein in E. coli

[0085] Among the plasmids prepared in Example 1, pHex-L3-CRM and pHex-L5-CRM were selected in consideration of the expression level and cell growth. They were transformed into the E. coli strains shown in Table 4 below, and the expression and expression location of CRM197 protein were investigated.

[0086] [Table 4]

[0087] The colonies formed in solid medium (soytone 10g / L, yeast extract 5g / L, NaCl 10g / L, agar 15g / L) were cultured in LB liquid medium containing 100mM potassium phosphate (pH7.5), KM 50μg / ml, and 0.2% lactose at 30℃ for 15 hours with shaking. Total cells were subjected to SDS PAGE, and the expression of CRM197 was analyzed using Coomassie Blue staining and Western blotting (Figure 4). In the case of L3 fusion, CRM197 protein was expressed in all strains used, but in the case of L5 fusion, only Origami TM When transformed into 2, it was unable to grow in liquid medium. Expression of CRM197 protein was observed in the other strains.

[0088] Example 2.1: CRM197 Expression by L5

[0089] BL21(DE3) containing pHex-L5-CRM was cultured in LB liquid medium (50 mL / 500 mL baffled flask) containing 100 mM potassium phosphate (pH 7.5) and 50 μg / mL KM. 600After culturing until the β-amino acid residue reached 0.4-0.6, expression was induced by adding 0.2%, 0.4%, or 0.6% lactose or 0.02 mM, 0.2 mM, or 2 mM IPTG (isopropyl β-D-1-thiogalactopyranosid) as an inducer. The culture temperature was 25°C or 30°C. After culturing, the cells were harvested and suspended in 50 mM potassium phosphate (pH 7.0), and then sonicated to disrupt the cells. After disruption, the supernatant (soluble fraction) and the precipitate (insoluble fraction) were separated by centrifugation. After SDS-PAGE of each sample, the expression of CRM197 protein was analyzed using Coomassie staining and Western blotting (Figure 5). When cultured at 25°C after adding an inducer (lactose, IPTG), most of the expressed CRM197 protein was present in a soluble form, and considering that the molecular weight was identical to that of the reference CRM197, the expressed protein was determined to be mature CRM197 with the L5 signal sequence removed (Figure 5A). On the other hand, when cultured at 30°C, about 50% of the CRM197 protein was found in the insoluble fraction when lactose was used as an inducer, and most of the CRM197 protein was found in the insoluble fraction when IPTG was added as an inducer (Figure 5B).

[0090] To confirm the expression location of CRM197, periplasmic fractions were collected using osmotic shock. The procedure is as follows: BL21(DE3) containing pHex-L5-CRM was cultured at 25°C, and the cells were harvested by centrifugation. The cells were incubated in a plasma membrane induction buffer solution [30 mM Tris-HCl (pH 8.0), 20% sucrose, 1 mM or 10 mM EDTA, 1 mM PMSF (Phenylmethylsulfonyl fluoride)] until the cell concentration reached OD 600After resuspending the cells at 10, they were stirred at room temperature for 0.5 to 1 hour. Then, the cells were harvested by centrifugation at 4,000 x g for 15 minutes, and the same amount of cold 30 mM Tris-HCl (pH 8.0) below 4 ° C was added and stirred at room temperature for 0.5 to 1 hour. Then, the cells were centrifuged at 4,000 x g for 15 minutes to obtain a supernatant (periplasmic fraction, P2). After treatment with the plasma membrane induction buffer, the supernatant (P1), periplasmic fraction (P2), and cytoplasmic fraction were developed using SDS-PAGE, and the expression and expression location of CRM197 were investigated using Coomassie staining and Western blotting (Figure 5). It was confirmed that L5 could successfully secrete CRM197 into the periplasm (Figure 6). As the plasma membrane induction buffer, EDTA was more effective when it was 10 mM than 1 mM.

[0091] Example 2.2: CRM197 Expression by L3

[0092] BL21(DE3) containing pHex-L3-CRM was expressed under the same conditions as in Example 2.1. CRM197 induced by L3 was present in a soluble form under all conditions, unlike L5 (Figure 7), and was confirmed to be secreted into the periplasm (Figure 8).

[0093] Example 3: Cultivation of E. coli BL21(DE3)

[0094] The BL21(DE3) strain containing pHex-L3-CRM or pHex-L5-CRM was cultured by the following method. During the main culture, feeding was performed using the pH stat method, and the pH was maintained at 7.3 using a feeding solution (600 g / L glucose, 30 g / L yeast extract) and an alkaline solution (14% to 15% ammonia). The solutions and medium compositions used in the culture are shown in Tables 5 and 6.

[0095] [Table 5]

[0096] [Table 6]

[0097] A single colony formed in modified LB agar medium [Modified Luria-Bertani (LB) agar: soytone 10g / L, yeast extract 5g / L, sodium chloride 10g / L, agar 15g / L, kanamycin 50mg / L] was inoculated into a seed culture medium and cultured at 30°C for 18 hours. This seed culture was again inoculated into a main culture medium (3L / 5L fermenter) at a ratio of 1% (v / v) and cultured at 30°C. The main culture medium was supplemented with 0.1% sterilized antifoaming agent. After the absorbance of the culture liquid reached a value of 30-40, the temperature was lowered to 25°C. Next, IPTG 10mM was added, and the culture was terminated after the absorbance of the culture liquid reached 100-120.

[0098] The culture pattern of E. coli BL21(DE3) containing pHex-L3-CRM in a 5L fermenter is shown in FIG. 9, and the culture pattern of E. coli BL21(DE3) containing pHex-L5-CRM is shown in FIG. 10. The expression pattern of CRM197 expressed during fermentation in a 5L fermenter is shown in FIG. 11, and the expression yield was 1.1 g / L to 1.2 g / L in the case of L3 fusion and 3.0 g / L to 3.7 g / L in the case of L5 fusion. CRM197 was quantified using a densitometer (GS-900) after SDS-PAGE / Coomassie staining. TM The relative quantity was compared with that of the reference CRM197 using a ELISA kit (Bio-Rad Laboratories Ins., Hercules, California) and quantified.

[0099] Example 4: Protein purification

[0100] Example 4.1: Preparation of periplasmic fraction from cell culture medium

[0101] The process for collecting the periplasmic fraction from cells cultured in a 5 L fermenter is as follows: The cell culture medium was centrifuged at 4,000 x g for 15 min at 4°C to pellet the cells. The cell pellet was resuspended in a plasma membrane induction buffer solution of protein modified based on an absorbance of 100 (Table 7) and stirred at room temperature for 0.5 to 1 h.

[0102] [Table 7]

[0103] The cells were then collected by centrifugation at 4,000 x g for 15 minutes, and the same amount of cold 30 mM Tris-HCl [pH 8.0] below 4°C was added and stirred at room temperature for 0.5 to 1 hour. The supernatant was then collected by centrifugation at 4,000 x g for 15 minutes, and impurities were removed using MF. SDS-PAGE analysis of the periplasmic fraction collected from E. coli BL21 (DE3) containing pHex-L3-CRM through the above process is shown in FIG. 12(A), and SDS-PAGE analysis of the periplasmic fraction collected from E. coli BL21 (DE3) containing pHex-L5-CRM through the above process is shown in FIG. 12(B). The amount of CRM197 protein present in the periplasmic fraction was confirmed to be 1.2 g / L for the L3 strain and 2.3 g / L for the L5 strain (Table 8).

[0104] [Table 8]

[0105] Example 4.2: Purification of CRM197 Protein

[0106] The periplasmic fraction of pHex-L3-CRM culture medium was collected and concentrated 2-fold using a 10 kDa cut-off membrane in a TFF system, and ultrafiltered with 10 volumes of 10 mM sodium phosphate solvent (pH 7.2). The purification was completed through two column steps using an AKTA pure (GE Healthcare) system. The first column step was anion exchange chromatography (Diethyl aminoetyl Separose Fast Flow resin, DEAE) used to remove nucleic acids and impurity proteins. DEAE resin is negatively charged, and positively charged proteins bind to it. The ultrafiltered sample was first subjected to DEAE chromatography to remove unbound proteins and impurities, and then through a washing process, impurity proteins with low binding strength, except CRM197, were removed depending on the salt concentration. The salt concentration was then increased to elute only CRM197. SDS-PAGE analysis was performed on a sample during the purification process using DEAE chromatography, and the results are shown in Figure 13(A). From the sample that had undergone DEAE chromatography, impurities and proteins that were not primarily bound were removed using HA (hydroxyapatite) chromatography in flow-through mode, and CRM197 was eluted with a final solvent of 100 mM potassium phosphate and 100 mM NaCl. The SDS-PAGE results of the eluted CRM197 are shown in Figure 13(B).

[0107] Example 5: Comparison with Corynebacterium-produced CRM197

[0108] The quality and characteristics of the final purified CRM197 were analyzed. Analysis by SEC-HPLC confirmed that the purity was over 99% (Figure 14). SDS-PAGE and Western blot analysis confirmed that a band appeared at the same position as CRM197 produced by Corynebacterium (Figure 15).

[0109] The entire sequence of the 535 amino acids that make up CRM197 was also confirmed to be 100% identical. The molecular weight measurement revealed a major peak at 58,409 Da, which matched the theoretical molecular weight value (Figure 16). Circular dichroism (CD) analysis was used to confirm the higher-order structure, confirming that there was no difference in the higher-order structure from CRM197 produced by Corynebacterium (Figure 17). Fluorescence spectrum analysis revealed that the maximum emission wavelength was 338 nm, the same as CRM197 produced by Corynebacterium (Figure 18).

[0110] From the above results, it was confirmed that CRM197 produced using E. coli pHex-L3 strain is physicochemically and immunologically identical to CRM197 produced by Corynebacterium. [Industrial Applicability]

[0111] According to the present invention, even in ordinary E. coli in which the redox potential is not adjusted, it is possible to express CRM197 protein having the same physicochemical / immunological properties as the protein isolated from the parent strain, and it is possible to produce CRM197 protein with high secretion efficiency into the periplasm even without changing the pH of the medium to increase secretion into the periplasm, which is very useful in producing CRM197 protein.

[0112] Although the specific parts of the present invention have been described in detail above, it is obvious to those skilled in the art that such specific techniques are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A nucleic acid encoding a signal peptide for expressing CRM197 protein that is highly efficiently secreted into the surrounding cytoplasm, wherein the nucleic acid is represented by the base sequence of SEQ ID NO:

8.

2. A nucleic acid construct comprising the nucleic acid of claim 1 and a gene for a CRM197 protein.

3. The nucleic acid structure according to claim 2 , wherein the CRM197 protein gene is represented by the base sequence of SEQ ID NO:

2.

4. An expression vector comprising the nucleic acid of claim 1 and a gene encoding a CRM197 protein.

5. The expression vector according to claim 4 , wherein the CRM197 protein gene is represented by the base sequence of SEQ ID NO:

2.

6. The expression vector of claim 4 further comprising a Trc promoter.

7. A recombinant microorganism into which the nucleic acid construct according to claim 2 or the expression vector according to claim 4 has been introduced.

8. The recombinant microorganism of claim 7 which is Escherichia coli.

9. A method for producing CRM197 protein comprising the steps of: (a) culturing the recombinant microorganism of claim 7 to produce CRM197 protein; and (b) isolating the produced CRM197 protein.

10. The method of claim 9, wherein step (b) comprises isolating CRM197 protein secreted into the periplasm.

Citation Information

Patent Citations

  • Expression system

    JP2013507113A

  • Fermentation process

    JP2014512185A

  • Methods and compositions related to CRM197

    JP2016501550A

  • Enhanced production of recombinant crm197 in E. coli

    JP2017508454A

  • CRM197 protein expression

    WO2019143911A1